Hansa Biopharma AB HNSA

Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and engineering platform for biologics. Hansa will use Cradle's end-to-end platform across its discovery pipeline to design, optimize, and advance novel therapeutic candidates. Leveraging Cradle's AI driven protein engineering platform, the companies aim to accelerate the development of new t

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

Despite a slight revenue dip, Hansa Biopharma AB (FRA:24H) strengthens its European presence and prepares for a significant U.S. market opportunity.

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and SERB S.A. ("SERB") today announced required regulatory approvals have been obtained and that the previously announced exclusive licensing transaction with SERB has closed.

BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa Biopharma. “Adding Idefirix to the SERB portfolio reflects SERB’s

Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival[*] and patient survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with Idefirix (imlifidase).

Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026.

Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing.

Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and commercialisation rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa for €115 million. Idefirix® is a differentiated treatmen

Despite a significant revenue drop, Hansa Biopharma AB (HNSBF) focuses on strategic financial moves and market expansion to bolster future growth.

The recent SEK 8 trim to the Hansa Biopharma price target, to SEK 69, sits alongside an unchanged fair value estimate of SEK 80.83, putting fresh attention on how risk is being priced in. That shift reflects a split in analyst views, with optimism around imlifidase milestones balanced against concerns about commercialization, regulatory timing, and potential reshaping of EU operations. Read on to see how these moving pieces shape the evolving Hansa Biopharma story and what to watch next. Stay...

Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025.